These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16869816)

  • 41. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy.
    Eardley I; Mirone V; Montorsi F; Ralph D; Kell P; Warner MR; Zhao Y; Beardsworth A
    BJU Int; 2005 Dec; 96(9):1323-32. PubMed ID: 16287454
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials.
    Fonseca V; Seftel A; Denne J; Fredlund P
    Diabetologia; 2004 Nov; 47(11):1914-23. PubMed ID: 15599697
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: a randomized, double-blind, parallel, placebo-controlled clinical study.
    Chen KK; Jiann BP; Lin JS; Lee SS; Huang ST; Wang CJ; Ju-Ton H; Su CK; Costigan TM; Emmick JT
    J Sex Med; 2004 Sep; 1(2):201-8. PubMed ID: 16422975
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib.
    Lauring B; Li XS; Liu Y; Corr C; Lazarus N; Cote J; Larson P; Levonas AO; Lasseter KC; Preston RA; Smith WB; Lai E; Wagner JA
    J Clin Pharmacol; 2014 Nov; 54(11):1247-55. PubMed ID: 24782116
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.
    Kaufmann P; Cruz HG; Krause A; Ulč I; Halabi A; Dingemanse J
    Br J Clin Pharmacol; 2016 Aug; 82(2):369-79. PubMed ID: 27062188
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tadalafil population pharmacokinetics in patients with erectile dysfunction.
    Trocóniz IF; Tillmann C; Staab A; Rapado J; Forgue ST
    Eur J Clin Pharmacol; 2007 Jun; 63(6):583-90. PubMed ID: 17431603
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Porst H; Giuliano F; Glina S; Ralph D; Casabé AR; Elion-Mboussa A; Shen W; Whitaker JS
    Eur Urol; 2006 Aug; 50(2):351-9. PubMed ID: 16766116
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction.
    McMahon C
    J Sex Med; 2005 May; 2(3):415-25; discussion 425-7. PubMed ID: 16422874
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies.
    Porst H; Gacci M; Büttner H; Henneges C; Boess F
    Eur Urol; 2014 Feb; 65(2):455-64. PubMed ID: 24119319
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction.
    Bruzziches R; Greco EA; Pili M; Francomano D; Spera G; Aversa A
    Curr Diabetes Rev; 2008 Feb; 4(1):24-30. PubMed ID: 18220692
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The efficacy and safety of tadalafil in United States and Puerto Rican men with erectile dysfunction.
    Seftel AD; Wilson SK; Knapp PM; Shin J; Wang WC; Ahuja S
    J Urol; 2004 Aug; 172(2):652-7. PubMed ID: 15247754
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
    Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
    Kearney BP; Yale K; Shah J; Zhong L; Flaherty JF
    Clin Pharmacokinet; 2006; 45(11):1115-24. PubMed ID: 17048975
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil.
    McMahon C
    J Sex Med; 2004 Nov; 1(3):292-300. PubMed ID: 16422959
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.
    Wrishko RE; Dingemanse J; Yu A; Darstein C; Phillips DL; Mitchell MI
    J Clin Pharmacol; 2008 May; 48(5):610-8. PubMed ID: 18305126
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tadalafil for treatment of erectile dysfunction in men on antidepressants.
    Segraves RT; Lee J; Stevenson R; Walker DJ; Wang WC; Dickson RA
    J Clin Psychopharmacol; 2007 Feb; 27(1):62-6. PubMed ID: 17224715
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
    Buvat J; Büttner H; Hatzimouratidis K; Vendeira PA; Moncada I; Boehmer M; Henneges C; Boess FG
    J Sex Med; 2013 Jun; 10(6):1592-602. PubMed ID: 23551622
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pharmacological, pharmacokinetic, and clinical profile of tadalafil (Cialis)].
    Yamaguchi T; Uenaka K; Imaoka T
    Nihon Yakurigaku Zasshi; 2008 Jun; 131(6):469-77. PubMed ID: 18552451
    [No Abstract]   [Full Text] [Related]  

  • 59. A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors.
    Montorsi F; Aversa A; Moncada I; Perimenis P; Porst H; Barker C; Shane MA; Sorsaburu S
    J Sex Med; 2011 Sep; 8(9):2617-24. PubMed ID: 21707928
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction.
    Padma-Nathan H
    Am J Cardiol; 2003 Nov; 92(9A):19M-25M. PubMed ID: 14609620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.